BGPT: Paper Review: Brain homogenates from human tauopathies induce tau inclusions in mouse brain

Explore by Goal

Quick Explanation Copied

Core claim: Human brain homogenates from multiple sporadic tauopathies induce formation of tau inclusions in mouse brains, including an apparent “prion-like” ability to propagate after serial transmission—while Aβ-rich material (and APP23×ALZ17 crossing) did not induce tau inclusions in this system.

Long Explanation

Paper review (visual-first): “Brain homogenates from human tauopathies induce tau inclusions in mouse brain”

DOI: 10.1073/pnas.1301175110
Authors: Clavaguera et al.
Study type: Rodent in vivo prion-like seeding assay using human brain homogenates.

What they did (1-liner): Injected homogenates from patient-confirmed AD/TD/PiD/AGD/PSP/CBD (or controls) into hippocampus/cortex of ALZ17 mice (human WT 4R tau transgenic) and into C57BL/6 mice; then quantified phospho-tau + Gallyas-Braak silver pathology over time, including serial transmission.

1) Evidence map (visual): “Which human tauopathy seeds which mouse pathology?”

Colors indicate whether the paper reports tau inclusions (silver and/or phospho-tau immunostaining) in injected recipient mice.
Note: This is a phenomenology map (presence/absence and qualitative constraints), not a mechanistic proof of “prion” transport.

Epistemic caution: This map condenses the authors’ staining/readouts into binary “reported positive” flags. A deeper comparison would require the paper’s exact quantification across figures/Supplement Dataset S1, which is not included in the prompt text.

2) Timecourse scaffold (visual): induction and progression windows

The paper evaluates recipients at 6, 12, and 15 months (ALZ17) and describes increasing aggregation over time for induced groups.

3) Specificity test: Aβ-rich material did not induce tau inclusions in this system

The authors report: (i) pathological Aβ is absent in several injected human extracts (AD/AGD show some Aβ deposition; but other tauopathies and controls are negative), and (ii) Aβ-rich APP23 extracts do not induce AT8/Gallyas-Braak-positive tau inclusions in ALZ17 mice (up to 18 months), nor does APP23×ALZ17 develop AT100/Gallyas-Braak tau inclusions.

4) Mechanistic interpretation (critical): “prion-like” vs “seeded aggregation” vs confounds

What the authors conclude: Once tau inclusions form, they become self-propagating and spread in a prion-like manner, supported by serial transmission experiments.

Main scientific strengths (evidence-based, from this paper)

Human-to-mouse relevance at the tissue level: total brain homogenates (soluble + insoluble fractions) from multiple neuropathologically confirmed sporadic tauopathies induce tau inclusions in recipient mice.
Disease-phenotype morphologic correspondence (within limits of histology): AGD-like grains, PSP-like tufted astrocytes, CBD-like astrocytic plaques, and PiD-like thick neuropil threads are reported as resembling originating pathologies.
Specificity control against Aβ-driven tau induction: Aβ-rich APP23 homogenate and APP23×ALZ17 crossing do not produce AT8/AT100/Gallyas-Braak-positive tau inclusions in ALZ17 recipients under the tested conditions.

Critical limitations & blind spots (what would change the interpretation)

Mechanistic ambiguity of “prion-like”: serial transmission supports seed-like behavior, but the paper excerpt emphasizes histological readouts (silver impregnation and phospho-tau antibodies) rather than direct biochemical purification of the seeding species. The authors note EM did not show filaments, plausibly due to detectability limits.
Species barrier / overexpression effects: inclusions are stronger in ALZ17 than in C57BL/6, consistent with recruitment efficiency differences or “species barrier” effects. Without full numeric tables here, it is difficult to separate recruitment efficiency, seeding competence, and detection sensitivity.
Confounds intrinsic to total homogenates: brain homogenates include many factors (lipids, nucleic acids, proteases, non-tau aggregates). The paper uses histologic and immunologic specificity (human- vs mouse-tau antibodies; Aβ-focused controls), but the exact tau species responsible for seeding is not resolved in the excerpt.
Neurodegeneration readouts may be underpowered for causality: the authors state signs of neurodegeneration were not observed up to 18 months, aligning with earlier work in the same platform; however, “no evidence” within a limited timeframe is not strong evidence of “no toxicity.”

5) “What would disprove this?” (falsification checklist)

Disproof should target:

Replicated negative controls: Independent labs would need to confirm that age-matched control homogenates do not induce silver-positive/AT100-positive tau inclusions under matched stereotaxic conditions.
Seed activity after rigorous fractionation: If seeding were attributable to non-tau confounders in total homogenates, fractionation/purification that removes tau would eliminate seeding, and reconstitution would pinpoint which factor(s) restore activity.
(This paper acknowledges EM detectability issues but does not provide seed-species purification in the excerpt.)
Aβ-specific negative inference: Demonstrating that Aβ-rich APP23 material truly lacks tau-seeding competence in this ALZ17 context is necessary for the specificity argument.

Confidence statement: Based on the provided full-text excerpt, the central phenomenological findings (tau inclusion induction + serial transmission + Aβ-negative controls) are supported with strong internal consistency in the methods/readouts described. However, the excerpt does not include the full numeric Dataset S1 values or detailed blinding/statistics procedures, which limits the strength of quantitative conclusions about efficiency and morphology specificity.

Author review links (bespoke next steps)

Use these to get author-specific follow-up perspectives on this exact paper.

Feedback:

Updated: March 26, 2026